Izmir Bozyaka Training and Research Hospital, Department of Urology, University of Health Sciences, Izmir, Turkey.
Department of Urology, Izmir Tinaztepe Galen Hospital, Izmir, Turkey.
Int Urogynecol J. 2022 Aug;33(8):2127-2132. doi: 10.1007/s00192-022-05250-1. Epub 2022 Jun 6.
We aimed to compare on-demand and continuous use of fesoterodine 4 mg concerning efficacy and adverse effects.
A total of 100 patients who were diagnosed with non-neurogenic overactive bladder (OAB) syndrome were included in the study. All patients were evaluated with MMSE, ICIQ-SF, SEAPI quality of health and OAB-V8 questionnaires, at the beginning, 1st month and 4th month. Fesoterodine 4 mg was started for treatment. At the end of the 1st month, patients who obtained benefit from the treatment were 1:1 randomized into two groups. In group 1, fesoterodine 4 mg was given 1 × 1 in a standard manner whereas in group 2 patients took the pills on demand. Both groups were evaluated for efficacy and adverse events at 4 months.
Final analyses included 69 patients. At 4-month follow-up, OAB-V8 scores were significantly improved compared to 1 month in both groups. Again at h months, no difference was detected between the two groups for MMSE, ICIQ-SF and SEAPI scores. In continuous usage group, 4th month MMSE scores were significantly lower than 1st month scores. At 4 months, dry mouth and constipation were lower in the on-demand group compared to continuous usage group.
Compared to standard continuous usage, on-demand usage of fesoterodine showed similar efficacy with fewer adverse events.
我们旨在比较按需使用和连续使用非索罗定 4 毫克在疗效和不良反应方面的差异。
本研究共纳入 100 例诊断为非神经源性膀胱过度活动症（OAB）的患者。所有患者均接受 MMSE、ICIQ-SF、SEAPI 健康质量和 OAB-V8 问卷评估，在开始时、第 1 个月和第 4 个月。开始使用非索罗定 4 毫克进行治疗。在第 1 个月结束时，从治疗中获益的患者以 1:1 的比例随机分为两组。在第 1 组中，非索罗定 4 毫克以标准方式 1×1 给药，而在第 2 组中患者按需服用。两组均在第 4 个月时评估疗效和不良反应。
最终分析包括 69 例患者。在第 4 个月随访时，与第 1 个月相比，两组 OAB-V8 评分均显著改善。同样在 h 个月时，两组间 MMSE、ICIQ-SF 和 SEAPI 评分无差异。在连续使用组中，第 4 个月的 MMSE 评分明显低于第 1 个月的评分。在第 4 个月时，按需组的口干和便秘发生率低于连续使用组。
与标准连续使用相比，按需使用非索罗定显示出相似的疗效，不良反应更少。
